In the asgt program, there is a faculty list--
with about 160 names on it. There are companies
represented, universities, and research institutes.
Seattle is represented by Targeted Genetics,
The University of Washington, and the Fred Hutchinson
Cancer Research Center. It is interesting to me that
gene therapy seems to have this image as the
illigitimate offspring of biotech, and yet there
seem to be so many serious scientists persuing it.
It is also hard to know where to put your money.
I'd like to see some merger activity...although
I guess that never did anything for Megabios and
GMED--although now that I've exited vlts it seems
to be doing better, ha! I am not crazy already
small companies spinning things off further,
obviously tgen spinning out CellExSys comes to
mind. ABGX/CEGE and now this Ceregene is another
example. Novartis should buy up everybody, then
I would know what to do <g>.
I've gone through the program only once, but the
first thing that jumps out at me, is that I do
not see Ariad all over the place. I do see Victor
Rivera as an abstract reviewer for gene
regulation though.
Unless you know hundreds of names, pulling out
the companies represented is a little tricky.
Finally, fwiw, the corporate sponsors include
Genstar, Introgen, and VirxSys--three companies
that I'm not at all familiar with.
off topic:
I was surfing and found that they fellow who
left Genset for Valigen, had now left Valigen!
That was Bernard Bahain. Valigen does not seem
to be doing so well...although the story I read
was a few months old. Actually, I think the blurb
I read was a biocentury freebie that I found in
the google cache. |
